|drug3140||Solution-Focused Support Program Wiki||1.00|
|drug3191||Standard of Care Wiki||0.15|
There is one clinical trial.
A total of 278 patients are planned. All patients will be in an early-stage of COVID-19. They must be adults and hospitalized. In this study, all participating patients will receive the standard treatment provided according to the current treatment protocols for coronavirus disease. In addition to this treatment, each patient will be randomly assigned to receive additional treatment with convalescent plasma transfusion (CP; blood plasma from patients who have been cured of coronavirus), or continue with standard treatment but without adding transfusion. 50% of the chances of additional treatment with CP, and 50% of the chances of receiving only the standard treatment for coronavirus. The duration of the study shall be one month from the assignment of the treatment. The patient and the doctor will know the treatment assigned.
Description: Proportion of patients in categories 5, 6 or 7 of the 7-point ordinal scale at day 15 Ordinal scale: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or ECMO. Death.Measure: Category Changes in Ordinal Scale Time: 15 days
Description: Time to change from baseline category to worsening into 5,6 or 7 categories of the ordinal scaleMeasure: Time to category 5, 6 or 7 of the ordinal scale Time: 29 days
Description: MortalityMeasure: Mortality of any cause at 15 days Time: 15 days
Description: MortalityMeasure: Mortality of any cause at 29 days Time: 29 days
Description: days free from oxygen supplementationMeasure: Oxygenation free days Time: 29 days
Description: days free from mechanical ventilationMeasure: Ventilator free days Time: 29 days
Description: Infusion-related adverse events Cumulative incidence of serious adverse events (SAEs) Cumulative incidence of Grade 3 and 4 adverse events (AEs).Measure: Incidence of Treatment-Emergent Adverse Events Time: 29 days
Description: Quantitative total antibodies and neutralizing antibody activity against SARSCoV-2 in the sera from donors and patients using viral pseudotypesMeasure: Antibodies levels in CP donors recovered from COVID-19 Time: 3 months
Description: Change in PCR for SARS-CoV-2 in naso/oropharyngeal swabs and blood at baseline and on days 3, 5, 8, 11 (while hospitalized); and days 15 and 29 (if able to return to clinic or still hospitalized).Measure: Viral load Time: Days 1,3,5,8,11 and 29
Description: Serum levels of CRP, lymphocyte count, LDH, D Dimer,IL-6, coagulation tests at baseline and days 3, 5, 8, 11, 15 and 29.Measure: Change in biological parameters Time: Days 1,3,5,8,11 and 29
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports